Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Akebia Therapeutics and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -7.07% | -137.67% | -5.13% |
| Vivos Therapeutics | -98.77% | -351.28% | -87.44% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 1 | 1 | 4 | 1 | 2.71 |
| Vivos Therapeutics | 1 | 2 | 2 | 0 | 2.20 |
Akebia Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 316.67%. Vivos Therapeutics has a consensus price target of $4.92, indicating a potential upside of 168.67%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Vivos Therapeutics.
Risk & Volatility
Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.89, meaning that its share price is 589% more volatile than the S&P 500.
Valuation and Earnings
This table compares Akebia Therapeutics and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $160.18 million | 2.39 | -$69.41 million | ($0.07) | -20.57 |
| Vivos Therapeutics | $15.03 million | 1.15 | -$11.14 million | ($1.77) | -1.03 |
Vivos Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Akebia Therapeutics beats Vivos Therapeutics on 12 of the 15 factors compared between the two stocks.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
